NCT03035331 - Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 15, 2017

Primary Completion Date

January 25, 2022

Study Completion Date

September 10, 2022

Conditions

Aggressive Non-Hodgkin LymphomaIndolent Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell LymphomaRecurrent T-Cell Non-Hodgkin LymphomaSmall Lymphocytic Lymphoma

Interventions

PROCEDURE

Cryosurgery

Undergo cryosurgery

BIOLOGICAL

Dendritic Cell Therapy

Given IT

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

BIOLOGICAL

Pneumococcal 13-valent Conjugate Vaccine

Given by injection

OTHER

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester